

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner



Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

DUR COMMITTEE AGENDA

Date: Tuesday, October 12, 2021
Time: 1:00PM to 2:30PM Closed Session, 2:30PM to 5:30PM Public Session
Location: Virtual: [Microsoft Teams Meeting](#)
Call in (audio only): 1-207-209-4724 Conference ID: 644404396#

- 1) Closed Session (1pm- 2:30pm)
 - Drug Financial Information Review
- 2) MaineCare Updates
- 3) Public Comments
- 4) Old Business
 - Approve June Meeting Minutes
 - Approve September Meeting Minutes
 - Vote on September New Drug Reviews:
 - Exservan (riluzole oral film)- ALS Drugs
 - Aduhelm (aducanumab-avwa)- Alzheimer- Cholinomimetics/Other
 - Elepsia XR (levetiracetam extended-release tablets)- Anticonvulsants
 - Jemperli (dostarlimab-gxly)- Cancer
 - Lumakras (sotorasib)- Cancer
 - Rybrevant (amivantamab-vmjw)- Cancer
 - Rylaze (asparaginase erwinia chrysanthemii(recombinant)-rywn)- Cancer
 - Truseltiq (infigratinib)- Cancer
 - Zynlonta (loncastuximab tesirine)- Cancer
 - Kerendia (finerenone)- Diuretics
 - Zegalogue (dasiglucagon)- Glucose Elevating Agents
 - Empaveli (pegcetacoplan)- Monoclonal Antibody
 - Ozobax (baclofen oral solution)- Muscle Relaxants
 - Kloxxado (naloxone hydrochloride)- Narcotic- Antagonists
 - Myfembree (relugolix, estradiol, and norethindrone acetate)- Pituitary Suppressive Agents, LHRH
 - Brexafemme (ibrexafungerp)- Antifungals- Assorted
 - Present Retro-DUR Results: Use of Long-acting Injectable Antipsychotics
- 5) Revised clinical criteria
 - None at this time
- 6) New Business (open session)
 - Present 2022 Meeting Schedule
 - Open session to review and vote categories subject to potential changes
 - Alzheimer/Antidementia Agents**
 - Analgesics, Narcotics, Short- Acting**
 - Analgesics/Anesthetics (Topical)**
 - Angiotensin Modulators**
 - Antiasthmatic - Antiinflammatory Agents**
 - Antibiotic- Cystic Fibrosis**
 - Anticoagulants**
 - Anticonvulsants**

Antihyperlipidemic/PCSK 9 Inhibitors
Antineoplastics
Antipsychotics
Antiretrovirals
Beta-Blockers
Bronchodilators, Beta Agonists
Colony Stimulating Factors
Contraceptives
COPD Agents
Cytokine and CAM Antagonists
Dermatologic- Scabicides/Ped/Atopic/Corticosteroids
DME- Diabetic Supplies
Endometriosis
Erythropoiesis Stimulating Proteins
GI- IBS/ OIC/CIC/ Antiemetics
Growth Hormones
Hematopoietics
Hemophilia
Hepatitis C Agents
Hyperuricemia and Gout
Hypoglycemics, Incretin Memetics
Hypoglycemics, Insulins & Related Agents
Hypoglycemics, Misc Agents
Idiopathic Pulmonary Fibrosis
Migraine
Movement Disorders
Multiple Sclerosis Agents
Neurotoxins
Ophthalmic Antibiotics
Ophthalmic Anti-inflammatories
Ophthalmic Modulators
Ophthalmics Antiallergics
Opiate Dependence & Overdose Treatments
Otic Anti Infectives
Pancreatic Enzymes
Platelet Aggregation Inhibitors
Platelet Stimulating Agents
Resp. Steriod/Anticholinergic/Misc
Sickle Cell Disease Agents
Neurologics-Spinal Muscular Atrophy (SMA) Agents
Stimulants & Related Agents
Urinary Antispasmodic
Vaginal Anti-Infectives

- 7) FDA Safety Alerts
- 8) Next Meeting (Tuesday, December 14, 2021 (from 5:30pm to 8:30pm))
- 9) Adjournment: 5:30PM